Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Sangamo Therapeutics, Inc (SGMO) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Sangamo Therapeutics, Inc. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1001233.
Total stock buying since 2014: $2,265,625.
Total stock sales since 2014: $84,054,463.
Total stock option exercises since 2014: $7,870,680.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 0 | $0 | 6,000,000 | $3,000,000 | 0 | $0 |
| 2022 | 21,784 | $79,011 | 500,000 | $2,657,300 | 0 | $0 |
| 2021 | 0 | $0 | 285,215 | $2,526,092 | 11,981 | $132,030 |
| 2020 | 28,000 | $163,535 | 65,795 | $534,643 | 74,907 | $330,900 |
| 2019 | 0 | $0 | 30,000 | $327,379 | 41,137 | $129,750 |
| 2018 | 11,408 | $145,531 | 203,059 | $3,698,265 | 208,908 | $1,189,896 |
| 2017 | 0 | $0 | 130,546 | $1,840,392 | 104,395 | $730,815 |
| 2015 | 0 | $0 | 504,501 | $7,183,477 | 494,000 | $2,890,412 |
| 2014 | 156,251 | $1,877,548 | 4,578,354 | $62,286,915 | 524,086 | $2,466,877 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2015-05-15 | Lanphier Edward O Ii (President & CEO) | Sale | 25,000 | 11.52 | 287,875 |
| 2015-05-15 | Lanphier Edward O Ii (President & CEO) | Option Ex | 25,000 | 6.82 | 170,500 |
| 2015-05-11 | Wolff Henry Ward (Exec VP & CFO) | Sale | 12,000 | 13.25 | 158,952 |
| 2015-05-11 | Wolff Henry Ward (Exec VP & CFO) | Option Ex | 10,000 | 3.45 | 34,500 |
| 2015-05-05 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Sale | 15,000 | 12.29 | 184,305 |
| 2015-05-05 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Option Ex | 15,000 | 3.45 | 51,750 |
| 2015-05-04 | Ringo William R | Sale | 3,000 | 12.98 | 38,928 |
| 2015-05-04 | Ringo William R | Option Ex | 3,000 | 6.23 | 18,690 |
| 2015-05-01 | Gregory Philip D (SVP of Research & CSO) | Sale | 15,000 | 12.62 | 189,375 |
| 2015-05-01 | Gregory Philip D (SVP of Research & CSO) | Option Ex | 15,000 | 4.83 | 72,495 |
| 2015-04-15 | Lanphier Edward O Ii (President & CEO) | Sale | 25,000 | 15.33 | 383,250 |
| 2015-04-15 | Lanphier Edward O Ii (President & CEO) | Option Ex | 25,000 | 6.82 | 170,500 |
| 2015-04-10 | Wolff Henry Ward (Exec VP & CFO) | Sale | 12,000 | 15.37 | 184,380 |
| 2015-04-10 | Wolff Henry Ward (Exec VP & CFO) | Option Ex | 10,000 | 3.45 | 34,500 |
| 2015-04-06 | Ringo William R | Sale | 2,200 | 14.95 | 32,881 |
| 2015-04-06 | Ringo William R | Option Ex | 2,200 | 6.41 | 14,102 |
| 2015-04-06 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Sale | 15,000 | 14.95 | 224,175 |
| 2015-04-06 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Option Ex | 15,000 | 3.45 | 51,750 |
| 2015-04-01 | Gregory Philip D (SVP of Research & CSO) | Sale | 15,000 | 15.15 | 227,190 |
| 2015-04-01 | Gregory Philip D (SVP of Research & CSO) | Option Ex | 15,000 | 4.83 | 72,495 |
| 2015-03-19 | Wolff Henry Ward (Exec VP & CFO) | Sale | 10,000 | 18.00 | 180,000 |
| 2015-03-19 | Wolff Henry Ward (Exec VP & CFO) | Option Ex | 10,000 | 14.27 | 142,700 |
| 2015-03-16 | Lanphier Edward O Ii (President & CEO) | Sale | 25,000 | 17.29 | 432,300 |
| 2015-03-16 | Lanphier Edward O Ii (President & CEO) | Option Ex | 25,000 | 6.82 | 170,500 |
| 2015-03-10 | Wolff Henry Ward (Exec VP & CFO) | Sale | 12,000 | 16.68 | 200,196 |
| 2015-03-10 | Wolff Henry Ward (Exec VP & CFO) | Option Ex | 10,000 | 3.45 | 34,500 |
| 2015-03-05 | Mento Steven J | Sale | 6,501 | 18.30 | 118,942 |
| 2015-03-05 | Mento Steven J | Option Ex | 10,000 | 4.54 | 45,400 |
| 2015-03-05 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Sale | 15,000 | 18.29 | 274,290 |
| 2015-03-05 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Option Ex | 15,000 | 3.45 | 51,750 |
| 2015-03-04 | Wolff Henry Ward (Exec VP & CFO) | Sale | 10,000 | 18.00 | 180,000 |
| 2015-03-04 | Wolff Henry Ward (Exec VP & CFO) | Option Ex | 10,000 | 14.27 | 142,700 |
| 2015-03-03 | Ringo William R | Sale | 2,200 | 17.21 | 37,862 |
| 2015-03-03 | Ringo William R | Option Ex | 2,200 | 6.41 | 14,102 |
| 2015-03-02 | Gregory Philip D (SVP of Research & CSO) | Sale | 15,000 | 17.26 | 258,945 |
| 2015-03-02 | Gregory Philip D (SVP of Research & CSO) | Option Ex | 15,000 | 7.12 | 106,800 |
| 2015-02-17 | Lanphier Edward O Ii (President & CEO) | Sale | 25,000 | 15.69 | 392,150 |
| 2015-02-17 | Lanphier Edward O Ii (President & CEO) | Option Ex | 25,000 | 6.82 | 170,500 |
| 2015-02-12 | Ramasastry Saira | Sale | 10,000 | 15.00 | 150,000 |
| 2015-02-12 | Ramasastry Saira | Option Ex | 10,000 | 5.03 | 50,300 |
| 2015-02-10 | Wolff Henry Ward (Exec VP & CFO) | Sale | 12,000 | 12.64 | 151,692 |
| 2015-02-10 | Wolff Henry Ward (Exec VP & CFO) | Option Ex | 10,000 | 3.45 | 34,500 |
| 2015-02-05 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Sale | 15,000 | 12.93 | 193,950 |
| 2015-02-05 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Option Ex | 15,000 | 5.13 | 77,025 |
| 2015-02-03 | Ringo William R | Sale | 2,200 | 12.70 | 27,940 |
| 2015-02-03 | Ringo William R | Option Ex | 2,200 | 6.41 | 14,102 |
| 2015-02-02 | Gregory Philip D (SVP of Research & CSO) | Sale | 15,000 | 12.86 | 192,825 |
| 2015-02-02 | Gregory Philip D (SVP of Research & CSO) | Option Ex | 15,000 | 4.83 | 72,495 |
| 2015-01-16 | Lanphier Edward O Ii (President & CEO) | Sale | 10,000 | 14.29 | 142,850 |
| 2015-01-16 | Lanphier Edward O Ii (President & CEO) | Option Ex | 10,000 | 6.82 | 68,200 |
| 2015-01-15 | Lanphier Edward O Ii (President & CEO) | Sale | 15,000 | 14.53 | 217,935 |
| 2015-01-15 | Lanphier Edward O Ii (President & CEO) | Option Ex | 15,000 | 6.82 | 102,300 |
| 2015-01-12 | Wolff Henry Ward (Exec VP & CFO) | Sale | 12,000 | 15.87 | 190,452 |
| 2015-01-12 | Wolff Henry Ward (Exec VP & CFO) | Option Ex | 10,000 | 3.45 | 34,500 |
| 2015-01-05 | Ringo William R | Sale | 2,200 | 15.20 | 33,429 |
| 2015-01-05 | Ringo William R | Option Ex | 2,200 | 6.41 | 14,102 |
| 2015-01-05 | Larson John William | Sale | 15,000 | 15.10 | 226,545 |
| 2015-01-05 | Larson John William | Option Ex | 15,000 | 6.40 | 96,000 |
| 2015-01-05 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Sale | 15,000 | 15.41 | 231,210 |
| 2015-01-05 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Option Ex | 15,000 | 6.82 | 102,300 |
| 2015-01-02 | Gregory Philip D (SVP, Research & CSO) | Sale | 15,000 | 15.78 | 236,670 |
| 2015-01-02 | Gregory Philip D (SVP, Research & CSO) | Option Ex | 15,000 | 7.12 | 106,800 |
| 2014-12-15 | Larson John William (Director) | Sale | 10,000 | 16.28 | 162,830 |
| 2014-12-15 | Larson John William (Director) | Option Ex | 15,000 | 5.72 | 85,800 |
| 2014-12-15 | Lanphier Edward O Ii (President & CEO) | Sale | 25,000 | 15.63 | 390,775 |
| 2014-12-15 | Lanphier Edward O Ii (President & CEO) | Option Ex | 25,000 | 4.11 | 102,750 |
| 2014-12-11 | Mento Steven J (Director) | Sale | 6,354 | 15.00 | 95,310 |
| 2014-12-11 | Mento Steven J (Director) | Option Ex | 10,000 | 4.10 | 41,000 |
| 2014-12-11 | Wolff Henry Ward (Exec VP & CFO) | Option Ex | 37,500 | .00 | 0 |
| 2014-12-09 | Larson John William (Director) | Sale | 10,000 | 12.00 | 120,000 |
| 2014-12-09 | Larson John William (Director) | Option Ex | 10,000 | 4.54 | 45,400 |
| 2014-12-05 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Sale | 15,000 | 11.21 | 168,195 |
| 2014-12-05 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Option Ex | 15,000 | 6.82 | 102,300 |
| 2014-12-01 | Gregory Philip D (SVP of Research & CSO) | Sale | 15,000 | 11.68 | 175,185 |
| 2014-12-01 | Gregory Philip D (SVP of Research & CSO) | Option Ex | 15,000 | 4.83 | 72,495 |
| 2014-11-17 | Lanphier Edward O Ii (President & CEO) | Sale | 25,000 | 11.23 | 280,850 |
| 2014-11-17 | Lanphier Edward O Ii (President & CEO) | Option Ex | 25,000 | 4.11 | 102,750 |
| 2014-11-12 | Larson John William (Director) | Sale | 10,000 | 12.00 | 120,010 |
| 2014-11-12 | Larson John William (Director) | Option Ex | 10,000 | 4.10 | 41,000 |
| 2014-11-10 | Wolff Henry Ward (Exec VP & CFO) | Sale | 2,000 | 11.37 | 22,748 |
| 2014-11-05 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Sale | 15,000 | 11.35 | 170,265 |
| 2014-11-05 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Option Ex | 15,000 | 5.46 | 81,975 |
| 2014-11-03 | Gregory Philip D (SVP of Research & CSO) | Sale | 15,000 | 11.91 | 178,710 |
| 2014-11-03 | Gregory Philip D (SVP of Research & CSO) | Option Ex | 15,000 | 5.33 | 79,950 |
| 2014-10-28 | Larson John William (Director) | Sale | 10,000 | 12.02 | 120,150 |
| 2014-10-28 | Larson John William (Director) | Option Ex | 10,000 | 7.28 | 72,800 |
| 2014-10-15 | Lanphier Edward O Ii (President & CEO) | Sale | 25,000 | 10.49 | 262,375 |
| 2014-10-15 | Lanphier Edward O Ii (President & CEO) | Option Ex | 25,000 | 4.11 | 102,750 |
| 2014-10-10 | Wolff Henry Ward (Exec VP & CFO) | Sale | 2,000 | 10.10 | 20,200 |
| 2014-10-06 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Sale | 15,000 | 10.72 | 160,860 |
| 2014-10-06 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Option Ex | 15,000 | 4.11 | 61,650 |
| 2014-10-01 | Gregory Philip D (SVP of Research & CSO) | Sale | 15,000 | 10.80 | 162,030 |
| 2014-10-01 | Gregory Philip D (SVP of Research & CSO) | Option Ex | 15,000 | 5.21 | 78,105 |
| 2014-09-15 | Lanphier Edward O Ii (President & CEO) | Sale | 25,000 | 12.13 | 303,375 |
| 2014-09-15 | Lanphier Edward O Ii (President & CEO) | Option Ex | 25,000 | 4.11 | 102,750 |
| 2014-09-10 | Wolff Henry Ward (Exec VP & CFO) | Sale | 2,000 | 12.31 | 24,620 |
| 2014-09-05 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Sale | 15,000 | 12.21 | 183,075 |
| 2014-09-05 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Option Ex | 15,000 | 4.11 | 61,650 |
| 2014-09-04 | Larson John William (Director) | Sale | 10,000 | 12.81 | 128,080 |
| 2014-09-04 | Larson John William (Director) | Option Ex | 10,000 | 7.73 | 77,300 |
| 2014-09-02 | Gregory Philip D (SVP of Research & CSO) | Sale | 15,000 | 13.45 | 201,795 |
| 2014-09-02 | Gregory Philip D (SVP of Research & CSO) | Option Ex | 15,000 | 5.21 | 78,105 |
| 2014-08-15 | Lanphier Edward O Ii (President & CEO) | Sale | 25,000 | 13.95 | 348,800 |
| 2014-08-15 | Lanphier Edward O Ii (President & CEO) | Option Ex | 25,000 | 4.11 | 102,750 |
| 2014-08-11 | Wolff Henry Ward (Exec VP & CFO) | Sale | 10,000 | 14.16 | 141,590 |
| 2014-08-11 | Wolff Henry Ward (Exec VP & CFO) | Option Ex | 8,000 | 7.28 | 58,240 |
| 2014-08-08 | Ramasastry Saira (Director) | Sale | 10,000 | 14.00 | 140,000 |
| 2014-08-08 | Ramasastry Saira (Director) | Option Ex | 10,000 | 5.03 | 50,300 |
| 2014-08-05 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Sale | 15,000 | 12.99 | 194,790 |
| 2014-08-05 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Option Ex | 13,202 | 4.11 | 54,260 |
| 2014-08-04 | Larson John William (Director) | Sale | 10,000 | 12.56 | 125,580 |
| 2014-08-04 | Larson John William (Director) | Option Ex | 10,000 | 4.00 | 40,000 |
| 2014-08-01 | Kolchinsky Peter | Sale | 27,770 | 12.82 | 356,094 |
| 2014-08-01 | Gregory Philip D (SVP of Research & CSO) | Sale | 15,000 | 12.54 | 188,145 |
| 2014-08-01 | Gregory Philip D (SVP of Research & CSO) | Option Ex | 15,000 | 5.21 | 78,105 |
| 2014-07-30 | Kolchinsky Peter | Sale | 109,590 | 12.44 | 1,362,751 |
| 2014-07-29 | Kolchinsky Peter | Sale | 1,407 | 12.41 | 17,463 |
| 2014-07-28 | Kolchinsky Peter | Sale | 60,081 | 12.11 | 727,400 |
| 2014-07-25 | Kolchinsky Peter | Sale | 47,429 | 12.31 | 583,945 |
| 2014-07-24 | Kolchinsky Peter | Sale | 124,050 | 12.28 | 1,523,209 |
| 2014-07-18 | Lanphier Edward O Ii (President & CEO) | Sale | 25,000 | 12.16 | 303,950 |
| 2014-07-18 | Lanphier Edward O Ii (President & CEO) | Option Ex | 25,000 | 4.11 | 102,750 |
| 2014-07-17 | Kolchinsky Peter | Buy | 37,215 | 12.26 | 456,218 |
| 2014-07-10 | Wolff Henry Ward (Exec VP & CFO) | Sale | 15,000 | 13.23 | 198,435 |
| 2014-07-10 | Wolff Henry Ward (Exec VP & CFO) | Option Ex | 13,000 | 7.50 | 97,565 |
| 2014-07-01 | Kolchinsky Peter | Sale | 82,700 | 16.00 | 1,323,282 |
| 2014-07-01 | Gregory Philip D (SVP of Research & CSO) | Sale | 15,000 | 15.66 | 234,870 |
| 2014-07-01 | Gregory Philip D (SVP of Research & CSO) | Option Ex | 15,000 | 5.21 | 78,105 |
| 2014-06-23 | Ramasastry Saira (Director) | Sale | 5,550 | 15.54 | 86,219 |
| 2014-06-23 | Ramasastry Saira (Director) | Option Ex | 5,550 | 5.03 | 27,916 |
| 2014-06-16 | Kolchinsky Peter | Sale | 250,500 | 16.50 | 4,132,999 |
| 2014-06-16 | Lanphier Edward O Ii (President & CEO) | Sale | 25,000 | 16.41 | 410,149 |
| 2014-06-10 | Wolff Henry Ward (Exec VP & CFO) | Sale | 15,000 | 15.62 | 234,360 |
| 2014-06-10 | Wolff Henry Ward (Exec VP & CFO) | Option Ex | 13,000 | 7.73 | 100,490 |
| 2014-06-09 | Kolchinsky Peter | Sale | 83,500 | 15.50 | 1,294,166 |
| 2014-06-09 | Mento Steven J (Director) | Sale | 4,328 | 15.00 | 64,920 |
| 2014-06-09 | Mento Steven J (Director) | Option Ex | 5,834 | 7.28 | 42,471 |
| 2014-06-06 | Kolchinsky Peter | Sale | 135,101 | 14.20 | 1,918,569 |
| 2014-06-05 | Kolchinsky Peter | Sale | 1,085,463 | 13.84 | 14,779,008 |
| 2014-06-04 | Kolchinsky Peter | Sale | 70,640 | 13.10 | 925,172 |
| 2014-06-03 | Kolchinsky Peter | Sale | 76,833 | 12.86 | 988,072 |
| 2014-06-02 | Gregory Philip D (SVP of Research & CSO) | Sale | 15,000 | 12.85 | 192,720 |
| 2014-06-02 | Gregory Philip D (SVP of Research & CSO) | Option Ex | 15,000 | 5.21 | 78,105 |
| 2014-05-30 | Kolchinsky Peter | Sale | 65,884 | 13.41 | 883,702 |
| 2014-05-29 | Kolchinsky Peter | Sale | 155,675 | 13.52 | 2,105,193 |
| 2014-05-28 | Kolchinsky Peter | Sale | 148,689 | 13.45 | 1,999,569 |
| 2014-05-27 | Kolchinsky Peter | Sale | 263,437 | 13.55 | 3,570,625 |
| 2014-05-27 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Sale | 15,000 | 13.57 | 203,520 |
| 2014-05-27 | Ando Dale G (VP, Therapeutic Dev. & CMO) | Option Ex | 15,000 | 4.32 | 64,800 |
| 2014-05-23 | Kolchinsky Peter | Sale | 51,597 | 13.27 | 684,692 |
| 2014-05-22 | Kolchinsky Peter | Sale | 56,396 | 13.54 | 763,714 |
| 2014-05-15 | Lanphier Edward O Ii (President & CEO) | Sale | 25,000 | 13.14 | 328,550 |
| 2014-05-13 | Kolchinsky Peter | Sale | 56,060 | 13.12 | 735,282 |
| 2014-05-12 | Kolchinsky Peter | Sale | 29,659 | 13.03 | 386,545 |
| 2014-05-12 | Wolff Henry Ward (Exec VP & CFO) | Sale | 15,000 | 12.85 | 192,735 |
| 2014-05-12 | Wolff Henry Ward (Exec VP & CFO) | Option Ex | 13,000 | 7.73 | 100,490 |
| 2014-05-08 | Kolchinsky Peter | Sale | 83,300 | 12.39 | 1,032,420 |
| 2014-05-07 | Kolchinsky Peter | Buy | 83,300 | 11.90 | 989,461 |
Insider trading activities including stock purchases, stock sales, and option exercises of SGMO listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Sangamo Therapeutics, Inc (symbol SGMO, CIK number 1001233) see the Securities and Exchange Commission (SEC) website.